1. Membrane Transporter/Ion Channel
    MAPK/ERK Pathway
    Stem Cell/Wnt
    NF-κB
  2. Sodium Channel
    MEK
    ERK
    NF-κB
  3. Lidocaine

Lidocaine (Synonyms: Lignocaine)

Cat. No.: HY-B0185 Purity: 99.52%
Handling Instructions

Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is a commonly used local anesthetics of amide derivative, a drug to treat ventricular arrhythmia and an effective tumor-inhibitor.

For research use only. We do not sell to patients.

Lidocaine Chemical Structure

Lidocaine Chemical Structure

CAS No. : 137-58-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
5 g USD 60 In-stock
Estimated Time of Arrival: December 31
10 g USD 96 In-stock
Estimated Time of Arrival: December 31
50 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Lidocaine:

Top Publications Citing Use of Products

    Lidocaine purchased from MCE. Usage Cited in: J Neuroinflammation. 2017 Nov 2;14(1):211.

    Immunoblot results demonstrate that Lidocaine inhibits Morphine-induced upregulation of phosphorylation of p38 MAPK, but not the p38 total protein.

    View All MEK Isoform Specific Products:

    View All ERK Isoform Specific Products:

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is a commonly used local anesthetics of amide derivative, a drug to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

    IC50 & Target[1,2]

    MEK

     

    ERK

     

    NF-κB

     

    In Vitro

    Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation[2].
    Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2].
    Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate[2].
    Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2].

    Cell Proliferation Assay[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Decreased significantly cell proliferation.

    Cell Viability Assay[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 1, 5 and 10 nM
    Incubation Time: 24, 48, 72 hours
    Result: Inhibited MKN45 cell viability.

    Apoptosis Analysis[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Increased significantly the apoptotic cell rate.

    Western Blot Analysis[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Down-regulated Cyclin D1 and up-regulated p21 expression significantly.
    In Vivo

    Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block[3].

    Clinical Trial
    Molecular Weight

    234.34

    Formula

    C₁₄H₂₂N₂O

    CAS No.

    137-58-6

    SMILES

    O=C(NC1=C(C)C=CC=C1C)CN(CC)CC

    Shipping

    Room temperature in continental US; may vary elsewhere

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (426.73 mM)

    H2O : ≥ 5 mg/mL (21.34 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.2673 mL 21.3365 mL 42.6730 mL
    5 mM 0.8535 mL 4.2673 mL 8.5346 mL
    10 mM 0.4267 mL 2.1337 mL 4.2673 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 99.52%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Lidocaine
    Cat. No.:
    HY-B0185
    Quantity: